Product news

Share this article:
The FDA has approved Eli Lilly's Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. The approval makes Cymbalta the first serotonin-norepinephrine reuptake inhibitor approved for reducing pain in patients with fibromyalgia. 

Allergan said the FDA has approved Trivaris (triamcinolone acetonide injectable suspension), a synthetic glucocorticoid corticosteroid with anti-inflammatory action to treat sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters